Toll-like receptors and IFN-α: Partners in autoimmunity

Journal of Clinical Investigation

Volumn 116, Issue 9, 2006, Pages 2319-2322

  Colonna, Marco ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; CYTOSOL RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; IMMUNIZATION; LIVER CELL; LIVER INJURY; MACROPHAGE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; T LYMPHOCYTE; VIRUS INFECTION;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; HUMANS; INTERFERON-ALPHA; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTORS;

EID: 33748306209     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29879     Document Type: Review

References (27)

1. Mathis, D., and Benoist, C. 2004. Back to central tolerance. Immunity. 20:509-516.
2. Abbas, A.K., Lohr, J., Knoechel, B., and Nagabhushanam, V. 2004. T cell tolerance and autoimmunity. Autoimmun. Rev. 3:471-475.
3. Fujinami, R.S., von Herrath, M.G., Christen, U., and Whitton, J.L. 2006. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin. Microbiol. Rev. 19:80-94.
4. Horwitz, M.S., and Sarvetnick, N. 1999. Viruses, host responses, and autoimmunity. Immunol. Rev. 169:241-253.
5. Von Herrath, M.G., Holz, A., Homann, D., and Oldstone, M.B. 1998. Role of viruses in type I diabetes. Semin. Immunol. 10:87-100.
6. Lang, K.S., et al. 2006. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 116:2456-2463. doi:10.1172/JCI28349.
7. Iwasaki, A., and Medzhitov, R. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-995.
8. Loetscher, M., et al. 1996. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184:963-969.
9. Lang, K.S., et al. 2005. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11:138-145.
10. Devendra, D., et al. 2005. Interferon-alpha as a mediator of polyinosinic:polycytidylic acid-induced type 1 diabetes. Diabetes. 54:2549-2556.
11. Sobel, D.O., et al. 1998. Low dose poly I:C prevents diabetes in the diabetes prone BB rat. J. Autoimmun. 11:343-352.
12. Sobel, D.O., and Ahvazi, B. 1998. Alpha-interferon inhibits the development of diabetes in NOD mice. Diabetes. 47:1867-1872.
13. Rifkin, I.R., Leadbetter, E.A., Busconi, L., Viglianti, G., and Marshak-Rothstein, A. 2005. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204:27-42.
14. Bennett, L., et al. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711-723.
15. Baechler, E.C., et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 100:2610-2615.
16. Krause, I., Valesini, G., Scrivo, R., and Shoenfeld, Y. 2003. Autoimmune aspects of cytokine and anticytokine therapies. Am. J. Med. 115:390-397.
17. Kono, D.H., Baccala, R., and Theofilopoulos, A.N. 2003. Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor. Autoimmunity. 36:503-510.
18. Theofilopoulos, A.N., Baccala, R., Beutler, B., and Kono, D.H. 2005. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23:307-336.
19. Frigerio, S., et al. 2002. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat. Med. 8:1414-1420.
20. Shiow, L.R., et al. 2006. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 440:540-544.
21. Le Bon, A., et al. 2003. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4:1009-1015.
22. Scarim, A.L., et al. 2001. Mechanisms of beta-cell death in response to double-stranded (ds) RNA and interferon-gamma: dsRNA-dependent protein kinase apoptosis and nitric oxide-dependent necrosis. Am. J. Pathol. 159:273-283.
23. Kato, H., et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 441:101-105.
24. Gitlin, L., et al. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. U. S. A. 103:8459-8464.
25. Smyth, D.J., et al. 2006. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet. 38:617-619.
26. Ronnblom, L., and Alm, G.V. 2003. Systemic lupus erythematosus and the type I interferon system. Arthritis Res. Ther. 5:68-75.
27. Jahnsen, F.L., Farkas, L., Lund-Johansen, F., and Brandtzaeg, P. 2002. Involvement of plasmacytoid dendritic cells in human diseases. Hum. Immunol. 63:1201-1205.